Korro Bio (KRRO) announced a collaboration with Novo Nordisk (NVO) to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience with Korro’s proprietary platform to develop RNA editing product candidates for two undisclosed targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio Board Changes and Strategic Advisor Agreement
- Korro Bio appoints Katharine Knobil to board of directors
- Korro to Participate in Upcoming September Investor and Scientific Conferences
- Starbucks, Chipotle upgraded: Wall Street’s top analyst calls
- Korro Bio initiated with an Outperform at William Blair